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ABSTRACT 
Background: Spectrophotometric analysis fulfils requirement where the simultaneous estimation of the drug 
combination can be done with similar effectiveness as that of chromatographic methods. Simultaneous 
estimation of drug combination is generally done by separation using chromatographic methods like HPLC, GC 
and HPTLC etc. These methods are accurate and precise with good reproducibility, but the cost of analysis is 
quite high owing to expensive instrumentation, reagent and expertise. Hence it is advisable to develop simpler 
and cost-effective method for simultaneous estimation of drugs for routine analysis of formulation. 
Methods: A descriptive study design was used and information was obtained through various literature reviews. 
RP-HPLC method was used and data was analyzed. 
Conclusion: The developed stability indicating HPLC method for quantitative estimation of olanzapine in bulk 
and pharmaceutical dosage forms is fast, simple, accurate, and more precise. Validation of this method was 
accomplished, getting results meeting all requirements. Thus, the developed HPLC method can be used for 
routine quality control test. 
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INTRODUCTION 
Simultaneous estimation of drug combination is generally done by separation using 
chromatographic methods like HPLC, GC and HPTLC etc. These methods are accurate and 
precise with good reproducibility, but the cost of analysis is quite high owing to expensive 
instrumentation, reagent and expertise.  Hence it is advisable to develop simpler and cost-
effective method for simultaneous estimation of drugs for routine analysis of formulation. 
Spectrophotometric analysis fulfils such requirement where the simultaneous estimation of 
the drug combination can be done with similar effectiveness as that of chromatographic 
methods [1].  
 
Basic criteria for new method development of drug analysis: 
• The drug or drug combination may not be official in any pharmacopoeias. 
• A proper analytical procedure for the drug may not be available in the literature 
due to patent regulations. 
• Analytical methods may not be available for the drug in the form of a formulation 
due to the interference caused by the formulation excipients. 
• Analytical methods for the quantitation of the drug in biological fluids may not be 
available. 
• Analytical methods for a drug in combination with other drugs may not be 
available. 
• The existing analytical procedures may require expensive reagents and solvents. It 
may also grip cumbersome extraction and separation procedures and these may 
not be reliable [1]. 
THEORY OF SPECTROPHOTOMETRY [1] 
Lambert’s Law 
when a beam of light is allowed to pass through a transparent medium the rate of decrease 
of intensity with the thickness is directly proportional to the intensity of light of incident light. 
Beer's law 
The intensity of a beam of monochromatic light decreases exponentially with the increase in 
concentration of the absorbing substance. The two separate laws prevailing absorption are 
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usually known as Lambert’s law & Beer’s law, Mathematically, the radiation concentration 
and radiation path length relation can be expressed: 
                   A = - log T = - log (It / I0)   = log (I0 / It) = ε .b .c 
Where        I0 = incident light intensity, A = absorbance  
                   b= cell path length in cm 
                   c= solution concentration in M/L, and ε = molar absorptivity 
 
 
INSTRUMENTATION       
It consists of a dual light source viz., tungsten lamp for visible range and deuterium lamp for 
ultraviolet region, grating monochromatic, photo-detector, mirrors and glass or quartz cells. 
For measurements to be made under visible region both glass and quartz cells can be used. 
For the measurements under ultraviolet region, only quartz cell should be used, since, glass 
cells absorb ultraviolet rays. 
There are two types of instrumental designs for this technique as single beam and double 
beam spectrophotometers. However double beam spectrophotometers are generally used 
and following is the sketch out of the instruments. 
 
 
 
Figure 1. Schematic diagram of double beam spectrophotometer 
Disadvantages 
Samples should be in solution. Mixture of substances poses tricky to analyze and requires 
prior separation. Interference from the sample’s matrix makes the measurement hard.1 
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Derivative Spectroscopy 
For the purpose of spectral analysis in order to relate chemical structure to electronic 
transitions, and for analytical situations in which combination contribute interfering 
absorption, a method of manipulating the spectral data is known as derivative spectroscopy.  
In the perspective of derivative spectrophotometry, the normal absorption spectrum is 
referred to as the fundamental, zero order, or D0 spectrum. The first derivative D1 spectrum 
is a plot of the rate of change of absorbance with wavelength against wavelength i.e. a plot 
of the slope of the fundamental spectrum against wavelength or a plot of dA/dλ vs. λ.  The 
maximum positive and maximum negative slopes respectively in the D spectrum correspond 
with a maximum and a minimum respectively in the D1 spectrum. The λmax in D spectrum is 
a wavelength of zero slope and gives dA/dλ = 0 in the D1 spectrum.  
The second derivative D2 spectrum is a plot of the curvature of the D spectrum against 
wavelength or a plot of d2A/ dλ2 v/s. λ. The maximum negative curvature in the D spectrum 
gives a minimum in the D2 spectrum, and the maximum positive curvature in the D spectrum 
gives two small maxima known as satellite bands in the D2 spectrum. 
Advantages:  
• Derivative spectrum shows better resolution of overlapping bands than the 
fundamental spectrum. 
• Permit the accurate determination of the λmax of the individual bands.  
                                                                            IJMS OCTOBER 2019/Vol 4/Issue 10 
International Journal of Medical Studies                                                                                                       5 
 
Figure 2. Different types of derivative spectrum 
Following drugs have been reported to be estimated simultaneously by the Derivative 
spectroscopy method [2, 3, 4, 5].  
• Estimation of Propranolol and Hydrochlorothiazide.  
• Estimation of Phenylpropanolamine, Chlorpheniramine and Bromhexine.  
• Estimation of Naphazoline hydrochloride and Chlorpheniramine maleate.  
 
 
COMPARISON OF DS WITH HPLC METHODS 
Although, chromatographic methods are characterized by high selectivity and sensitivity, and 
are giving reliable results, they need classy equipment and demand highly skilled operating 
personnel. The HPLC method has been highly used in the quality control of drugs for the 
reason that of its sensitivity, reproducibility and specificity. On the other hand, the DS method 
is very simple, rapid, and economical and allows the determination of drugs with sufficient 
reliability. DS method is selective, accurate, precise and excellent alternative to the HPLC 
method. spectrophotometry is a very good tool for fine resolution of spectra. It provides much 
improved fingerprints than traditional absorbance spectra. It is able to stifle matrix effects. 
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Dual wavelength method 
In dual wavelength method from the overlain spectra for estimation of a drug two 
wavelengths are chosen in such a way where the absorbance of other drug (interfering 
compound) is similar, so that the absorbance difference at these wavelengths are directly 
proportional to the concentration of that drug [6].  
 
Following drugs have been reported to be estimated simultaneously by the Dual wavelength 
method.  
• Estimation of Famotidine and Domperidone [6].  
• Estimation of Simvastatin and Ezetimibe [7].  
• Estimation of Atorvastatin and Amlodipine Besylate [8]. 
 
 
METHOD DEVELOPMENT  
Five stages are to be taken into consideration when starting new HPLC method. 
1) Instrumentation 
2) Determination of molecular characteristics of sample  
3) Selection of column 
4) Selection of mobile phase 
5) Selection of detector 
 
 
HPLC INSTRUMENTATION [6, 7, 8, 9] 
Liquid chromatography (LC) is a physical separation procedure conducted in the liquid phase. 
A sample is separated into its constituent components (or analytes) by distributing among the 
mobile phase (a flowing liquid) and a stationary phase (sorbents packed inside a column). 
HPLC is a modern form of LC that uses small-particle columns through which the mobile phase 
is pumped at high pressure. 
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Figure 3.   HPLC Instrumentation. 
 
SEPARATION MECHANISM 
Compounds are separated since the molecules travel at different rates in the column. Due to 
different interaction between stationary phase and different sample, the molecules move at 
different rate, therefore separation can be done. 
 
 
Figure 4. HPLC Separation mechanism 
 
Types of HPLC 
I Based on modes of chromatography  
 a) Normal-Phase Chromatography (NP HPLC) 
In NP HPLC, stationary phase is polar in nature and mobile phase is non polar solvents (such 
as hexane, heptane, etc.), In this technique, non-polar compound travel faster and are eluted 
first. This is because less affinity among solute and stationary phase. Polar compounds are 
                                                                            IJMS OCTOBER 2019/Vol 4/Issue 10 
International Journal of Medical Studies                                                                                                       8 
retained for longer time in column because of more affinity towards stationary phase. NP uses 
mainly non polar solvents and it is the method of preference for highly hydrophobic 
compounds. 
 
b) Reversed-Phase HPLC (RP HPLC or RPLC) 
As opposed to normal-phase HPLC, reversed-phase chromatography is based mainly 
dispersive forces (hydrophobic or Vander Waals interactions). The polarities of mobile and 
stationary phases are reversed, such that the surface of the stationary phase in RP-HPLC is 
hydrophobic and mobile phase is polar, where mainly water-based solutions are employed. 
Reversed-phase HPLC is by far the most admired mode of chromatography. Almost 90% of all 
analyses of low-molecular-weight samples are performed out by using RP HPLC. Less polar 
(more hydrophobic) analytes are more attracted and spend more time linked with the 
hydrophobic bonded phase, therefore, they are eluted at last. 
             
 
Figure 5. RP- HPLC Separation mechanism 
 
II Based on elution technique 
a) Isocratic elution: A separation in which the mobile phase composition remains unchanged. 
The mobile phase may comprise of a single solvent or a pre-mixed mixture of solvents.  
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b) Gradient elution: The composition of the mobile phase is changed during the separation. 
Two or three solvents that differ in polarity are employed. After sample introduction, the ratio 
of these solvents is planned to vary either continuously or in steps, ensuing in enhanced 
separation efficiency. The terms ‘binary gradient’, ternary gradient’, and quaternary gradient’ 
refer to the use of 2, 3, and 4 solvents, respectively, to make up the mobile phase composition 
in a gradient elution method. 
 
 
DETERMINATION OF MOLECULAR CHARACTERISTICS OF SAMPLE  
Methods for analyzing drugs in multicomponent dosage forms can be developed, provided 
one has knowledge about the nature of the sample, namely, its molecular weight, polarity, 
ionic character and the solubility parameter [10].  
Solubility in different organic or aqueous solvents determines the best composition of the 
sample solvent. PKa determine the pH in which the analyte will exist as a neutral or ionic 
species. When the pH = pKa, for the analyte, at this concentration equal proportion ionic and 
non-ionic species exists. As a general rule pH caused changes in retention occurs within ±1.5 
units above or below the pKa to ensure practically100% unionization for retention reason. 
This information will smooth the progress of an efficient sample extraction scheme and 
determine the optimum pH in mobile phase to achieve good separations [11]. 
 
 
SELECTION OF COLUMN 
Column is the heart of HPLC system. Good silica and bonding process will provide the 
reproducible and symmetrical peaks necessary for exact quantification [12]. 
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Column selection basics (Rule of thumb) 
 
Figure 6. (a) Selection of column in HPLC. 
 
 
Figure 6. (b) Selection of column in HPLC. 
 
SELECTION OF MOBILE PHASE 
The selection of mobile phase based on the nature and physicochemical properties of the 
analytes to be determined. Since the mobile phase governs solute-stationary phase 
interactions, its choice is decisive.  
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• Practical considerations utter that it should not degrade the equipment or the column 
packing. For this reason, strong acids, bases and halide solutions should be avoided. 
• Viscosity should be less than 0.5 centipoise; otherwise higher pump pressures are 
required and mass transfer between solvent and stationary phase will be reduced. For 
LC/MS only volatile buffers are used. 
• The mobile phase should have a pH 2.5 and 7.0 to maximize the lifetime of column. 
• Reduce cost and toxicity of the mobile phase by means of methanol instead of 
acetonitrile when possible.  
 
SELECTION OF DETECTOR 
There is little use in running a separation if the detector one uses cannot "see" all the 
components of interest, or conversely, if it"sees" too much. UV-vis detectors are the most 
popular as they can detect a broad range of compounds and have a fair degree of selectivity 
for some analytes. Unfortunately, UV-vis detectors are not universal detectors so it is 
worthwhile to look at the chemical structure of the analyte to see if it has suitable 
chromaphores, such as aromatic rings, for UV-vis detection [13]. Some of the detectors are 
described below in table. 
Table 1. Detectors 
Detector Analytes Solvent Requirements Comments 
UV-Visible Any with 
chromophores 
UV-grade non-UV 
absorbing solvents 
Has a degree of selectivity 
and useful for many HPLC   
applications. 
Fluorescence 
 
Fluorescent 
compounds 
 
UV-grade non-UV 
absorbing solvents 
Highly selective and 
sensitive and used to 
analyze derivatized 
compounds. 
Refractive Index 
(RI) 
Compounds with a 
different RI to the 
mobile phase 
Cannot run mobile 
phase gradients 
Virtually a universal detector 
but has limited sensitivity 
Conductivity Charged or polar 
compounds 
Mobile phase must be 
conducting 
Excellent for Ion Exchange 
methods 
                                                                            IJMS OCTOBER 2019/Vol 4/Issue 10 
International Journal of Medical Studies                                                                                                       12 
Electrochemical 
 
Readily oxidized or 
reduced compounds 
Mobile phase must be 
conducting 
Very Selective and sensitive 
 
Evaporative Light 
Scattering (ELSD) 
Virtually all 
compounds 
Must use volatile 
solvents and volatile 
buffers 
A universal detector which is 
highly sensitive and non-
selective 
Mass 
Spectrometer 
(MS) 
 
Broad range of 
compounds 
 
Must use volatile 
solvents and 
volatile buffers 
 
Highly sensitive and is a 
powerful 2nd dimensional 
analytical tool. Many modes 
are available. 
 
 
ANALYTICAL METHOD VALIDATION 
The process of establishing documented evidence which provides a high degree of assurance 
that the method does what it is intended to do. 
 
Positioning of validation in method development process 
 
 
Figure 7.  Positioning of validation in method development process. 
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 STABILITY STUDIES 
Stability is defined as the capacity of a drug substance or drug product to remain within 
established specifications to sustain its identity, strength, quality, and purity all over the retest 
or expiration dating periods [14]. 
Stability plays an important role in the drug development process. It explains several factors 
that influence the expiration dating of drug products, including the chemical and physical 
stability during the pre-clinical formulation stages, process development, packaging 
development, and post-marketing life [16].  
Stability testing allows the establishment of suggested storage conditions, retest periods, and 
eventually product shelf-life and expiry dating. In pharmaceutical field stability studies finds 
an application in the following areas of drug development program [17, 18, 19, 20]. 
 
 
 
Figure 8. Stability studies to support development of new drug product components of a film-
coating or capsule shell. For combination parenteral or aerosol products, the guidance 
recommends an exploration of the chemical compatibility or stability of multiple actives that 
will be combined before administration [24, 25].  
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Study Protocol [21, 22, 23] 
A general protocol for conducting forced degradation studies, shown in Table. 
 
Table 2. General protocol for stress testing of drug substances and drug products 
 
Condition 
Drug Substance Drug Product 
Solid Solution/ 
Suspension 
Solid (Tablets, 
Capsules, Blends) 
Solution (IV, 
Oral 
Suspension) 
Acid/base  √  X 
Oxidative X √ √ √ 
Photostability √ X √ √ 
Thermal √  √ √ 
Thermal/humidity √  √  
 
√= recommended; X = optional, suggested for some compounds [26-29]. 
 
Conditions for Stress Testing 
Specific parameters for stress testing of drug substance and drug product are shown in tables, 
respectively, describing the different stress conditions and range of exposure times.  
The desired target extent of degradation is approximately 5–20%. This is achieved by varying 
the stress conditions, for example, exposure time, temperature, or concentration of stressing 
agent (acid, base, oxidizer, etc.). Overstressing may destroy the compound or may lead to 
further degradation of the relevant primary degradants. Under-stressing may fail to create 
important degradation products.  
The degradation studies should be terminated after the maximum recommended time/stress 
conditions, even if sufficient degradation has not been achieved. It is unnecessary and even 
imprudent to try to degrade the drug at all cost as it would only increase the complexity of 
the method development with little or no benefit in the quality of the data generated by the 
method. The concentration of drug in the stressed sample solution may affect the target level 
of degradation that is eventually achieved.  
Therefore, lowering the drug concentration may help to increase degradation when 
necessary. Additional recommendations for preparation of the stressed samples follow [30]:  
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If the solid drug substance is unstable to thermal stress at high temperature due to melting, 
decomposition, use a lower temperature with longer stress time. 
 
Reaction Mechanism/Degradation Pathway 
The common reaction mechanisms of chemical degradation of pharmaceutical compounds 
consist of hydrolysis, oxidation, isomerization/epimerization, decarboxylation, 
rearrangement, dimerization/polymerization, photolysis, and reactions with excipients and 
salt forms [31, 32].  
 
Table 3. Common degradation routes for functional group 
Functional group Degradation route Degradants 
Acetals  
 
Hydrolysis 
Ketones /aldehydes /alcohols 
Esters/lactones Acids/alcohols 
Amides/lactams Amines/acids 
Alkenes Alcohols 
2◦ and 3◦ Amines  
 
 
Oxidation 
(radical, light, metal, 
peroxide mediated) 
N-oxide, hydroxylamine 
Thiols Disulfide 
Thioethers Sulfoxide, sulfone 
Alkenes Epoxide 
Allylic Alcohols α, β, unsaturated ketones 
Aldehyde Acids 
Alcohol Ketones, acids 
Oxazoles/imidazoles Various products 
Dienes (able to aromatized) Aromatic rings 
Benzyl/Allylic groups Benzylic/allylic alcohols 
 
 
Stability Indicating Assay Methods (SIAM) 
ICH defines SIAM as quantitative analytical methods that are based on the characteristic 
structural, chemical or biological properties of each active ingredient of a drug product and 
that will differentiate each active ingredient from its degradation products so that the active 
ingredient content can be accurately measured. 
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USFDA defines SIAM as validated quantitative analytical methods that can detect the changes 
with time in the chemical, physical, or microbiological properties of the drug substance and 
drug product, and that are specific so that the contents of active ingredient, degradation 
products, and other components of interest can be perfectly measured without interference 
[33, 34, 35]. 
Specific SIAM is defined as ‘a method that is able to measure unambiguously the drug(s) in 
the presence of all degradation products, excipients and additives, expected to be present in 
the formulation’. 
Selective SIAM is defined as ‘a method that is able to measure unequivocally the drug(s) and 
all degradation products in the presence of excipients and additives, expected to be present 
in the formulation’. 
 
Stability-indicating method development 
 
 
Figure 9. Stability-indicating method development process 
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DRUG PROFILE 
OLANZAPINE 
Olanzapine is an atypical antipsychotic, approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of schizophrenia and bipolar disorder. Olanzapine is 
structurally similar to clozapine and quetiapine, but is classified as a thienobenzodiazepine. 
The olanzapine formulations are manufactured and marketed by the pharmaceutical 
company Eli Lilly and Company; the drug went generic in 2011. 
 
Structural formula of Olanzapine 
 
 
Chemical Name 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-
b][1,5] benzodiazepine 
Molecular Formula C17H20N4S 
CAS no. 132539-06-1 
Molecular Weight 312.4 
Description A yellow crystalline powder  
Solubility Freely soluble in dichloromethane, insoluble in water 
Bioavailability 93% 
Half life 21-54 hrs 
Melting Point 195°C (383°F) 
U V max. 259 nm 
Category Anti-psychotic 
 
MECHANISM OF ACTION  
Olanzapine is an antagonist at types 1, 2 and 4 dopamine receptors. Olanzapine’s 
antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with 
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greater activity at serotonin 5-HT 2 receptors than at dopaminetype 2 receptors. Antagonism 
at muscarinic receptors. H1 receptors, and alpha (1) - receptors also occurs with olanzapine. 
 
 
USES 
• Oral formulation used in acute and maintenance treatment of Schizophrenia in adults, 
acute treatment of manic or mixed episodes associated with Bipolar I Disorder 
(monotherapy and in combination with lithium or valproate). 
• Intramuscular formulation used in acute agitation associated with Schizophrenia and 
Bipolar I Mania in adults. 
• Oral formulation combined with fluoxetine used in acute treatment of depressive 
episodes associated with Bipolar I Disorder in adults, or acute treatment of treatment 
resistant depression in adults. 
SIDE EFFECTS 
Side effects seen with olanzapine include 
• akathisia (an inability to sit still) 
• constipation 
• dizziness 
• drowsiness 
• insomnia 
• dry mouth 
• orthostatic hypotension 
 
ANALYTICAL METHOD DEVELOPMENT BY HPLC [36,37] 
Mobile Phase Selection 
Initially to estimate Olanzapine number of mobile phases in different ratio were tried. Results 
were shown in table. 
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Taking into thought the system suitability parameter like RT, Tailing factor, no. of theoretical 
plates and HETP, the mobile phase found to be most suitable for analysis was 1.75 gm KH2PO4 
in 1000 ml of water add 1 ml of TEA and adjust the pH 6 with OPA .The mobile phase was 
filtered through 0.45 µm filter paper to remove particulate matter and then degassed. Flow 
rate employed for analysis was 1.0 ml/min.         
 
Selection of wavelength 
100 mg of Olanzapine was weighed accurately and transferred to a 100 ml volumetric flask, 
and the volume was adjusted to the mark with the mobile phase. From above  solutions of 
0.1 ml was  transferred to 10 ml volumetric flasks, and make up the volume up to mark. 
Resulting solution was scanned over UV range (200-400nm), maximum absorbance was found 
at λmax 257.0.                                                            
 
Preparation of Standard Stock Solution 
10mg of Olanzapine was weighed accurately and transferred to separate 10ml volumetric 
flask, and the volume was adjusted to the mark with the Water : Acetonitrile (50:50 v/v) to 
give a stock solution of 1000ppm. 
 
Preparation of Working Standard Solution 
From stock solutions of Olanzapine 1 ml was taken and diluted up to 10 ml from this solution 
0.5, 1.0, 1.5, 2.0, 2.5 ml solutions were transferred to 10ml volumetric flasks and make up the 
volume up to 100 ml with Water : ACN (50:50 v/v) , gives  standard drug solution of 5, 10, 15, 
20, 25 µg/ ml concentration. 
  
ANALYSIS OF TABLET FORMULATION 
Assay of tablet formulation 
For analysis of the tablet formulation, weight equivalent to weight 10 mg of Olanzapine was 
transferred to 10 ml volumetric flask and dissolved in mobile phase. The solution was shaking 
vigorously for 20 mins and filtered through Whatman filter paper no. 41, then volume was 
made up to mark with mobile phase. From the above solution 1 ml of solution was taken and 
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diluted to 10 ml with mobile phase to get a solution containing 100 µg/ml. From the above 
solution 1 ml of solution was taken and diluted to 10 ml with mobile phase to get a solution 
containing 10 µg/ml of Olanzapine. The amounts of Olanzapine in tablet formulation were 
calculated by extrapolating the value of area from the calibration curve. Analysis procedure 
was repeated six times with tablet formulation. 
 
VALIDATION 
Linearity 
Linearity of analytical procedure is its ability (within a given range) to obtain test, which are 
directly proportional to area of analyte in the sample. The calibration plot was contracted 
after analysis of five different (from 5 to 25 µg/ ml ) concentrations and areas for each 
concentration was recorded three times, and mean area was calculated. The regression 
equation and correlation coefficient of curve are given and the standard calibration curve of 
the drug is shown in Figure 8.9. From the mean of AUC observed and respective concentration 
value, the response ratio (response factor) was found by dividing the AUC with respective 
concentration [38,39]. 
 
Accuracy 
Recovery studies were performed to validate the accuracy of developed method. To 
preanalysed sample solution, a definite concentration of standard drug (80%, 100%, and 
120%) was added and then its recovery was analyzed.  
 
Precision 
a) Repeatability 
Standard dilutions were prepared and three replicates of each dilution were analyzed in same 
day for repeatability and results were subjected to statistical analysis. (Table no. 8.11). 
Standard dilutions were prepared and three replicates of each dilution were analyzed in 
different days and by different analysts. Statistical analysis was carried out. 
b) Intermediate Precision 
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I. Day to Day 
The statistical analysis method was carried out and the data is presented in table. 
II. Analyst to Analyst 
The intermediate precision expresses with in laboratories variation (different days, different 
analysts, different equipment etc). The standard dilution was prepared and three replicate of 
each dilution were analyzed by different analysts for all the developed methods.  
 
Robustness 
As per ICH norms, small, but deliberate variations, by altering the pH and concentration of 
the mobile phase were made to check the method capacity to remain unaffected. The effect 
of change in pH of mobile phase, flow rate, mobile phase ratio on the retention time, 
theoretical plates, area under curve and percentage content of Olanzapine was studied.  
 
Forced Degradation studies  
In order to determine whether the method is stability indicating, forced degradation studies 
were conducted on olanzapine powder and the analysis was carried out by HPLC with a U.V. 
detector.  
 
Acid degradation: 
50 mg of olanzapine sample was taken into a 50 ml round bottom flask, 50 ml of 0.1 M HCl 
solution was added and contents were mixed well and kept for constant stirring for 8 h at 
80ºC. Samples were withdrawn and diluted to get 10 µg/ml subjected to HPLC and calculate 
the percentage degradation using calibration curve of Olanzapine.  
 
Base degradation 
50 mg of olanzapine sample was taken into a 50 ml round bottom flask, 50 ml of 0.1 M NaOH 
solution was added and contents were mixed well and kept for constant stirring for 8 h at 
80ºC. Samples were withdrawn and diluted to get 10 µg/ml subjected to HPLC and calculate 
the percentage degradation using calibration curve of Olanzapine.   
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Hydrolytic degradation 
50 mg of olanzapine sample was taken into a 50 ml round bottom flask, 50 ml of water was 
added and the contents were mixed well and kept for constant stirring for 48 h at 80ºC. 
Samples were withdrawn and diluted to get 10 µg/ml subjected to HPLC and calculate the 
percentage degradation using calibration curve of Olanzapine. 
 
Oxidative degradation:  
50 mg of olanzapine sample was taken into a 50 ml round bottom flask, 50 ml of 3% hydrogen 
peroxide solution was added, and contents were mixed well and kept for constant stirring for 
24 hr at room temperature. Samples were withdrawn and diluted to get 10 µg/ml subjected 
to HPLC and calculate the percentage degradation using calibration curve of Olanzapine.   
 
Thermal degradation 
50 mg of olanzapine sample was taken in to a petri dish and kept in oven at 50ºC for 4 weeks 
[40,41]. 
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RESULTS AND DISCUSSION                              
Result of FTIR of Olanzapine 
FTIR Spectrum
 
Figure 10. FTIR spectra of Olanzapine 
 
Interpretation of FTIR  
Table 4. Interpretation of FTIR spectra of Olanzapine 
S.No. Functional Group Experimental peak 
No.( cm-1) 
Theoretical peak No.( 
cm-1) 
1 OH- stretching vibration single bridge 3565.69 3570-3450 
2 -N=C=N- stretching vibrations 2171.25 2175-2130 
3 -C-C- multiple bond stretching  1964.27 1960 
4 Anhydride stretching vibration, saturated 
5-membered ring 
1889.97 1890-1750 
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5 Anhydride stretching vibrations, saturated 
acyclic 
1771.24 1790-1740 
6 -C=N- stretching vibration 1646.19 1660-1630 
7 N-H bending vibration, secondary amides 1515.62, 1540.45 1550-1510 
8 Sulfur compound 1139.06 1200-1050 
 
 
Results of Solubility Study  
Table 5. Solubility of Olanzapine 
S. No. 
Solvent Solubility 
1 Water Insoluble 
2 0.1 N HCl Freely soluble 
3 Methanol Freely soluble 
4 Ethyl alcohol Slightly soluble 
5 0.1 N NaOH Insoluble 
6 Acetonitrile Freely soluble 
7 Phosphate buffer  pH 7.4 Insoluble 
8 Benzene Freely soluble 
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Determination of λmax of Drug: - 257.0 nm 
 
Figure 11. Selection of λmax of Olanzapine 
 
 
Results of RP-HPLC Method 
System Suitability Parameters 
 
 
 
 
 
          Bonded Phase Octadecylsilane (C18) 
Mobile Phase  
 Buffer 60 
ACN 40 
Flow rate 1ml/min 
Temperature Room temp. 
Sample Size  20 µl 
Detection wavelength  257.0 nm 
Retention time Olanzapine 3.476 + 0.3 min     
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Table 6. Result of System Suitability Parameters for Olanzapine 
System suitability 
Parameter → 
RT AUC Theoretical 
plates 
Tailing factor 
Rep-1 2.375 
1251.23 
3078 1.18 
Rep-2 
2.374 
1250.458 
3056 1.20 
Rep-3 
2.375 
1256.658 
3098 1.15 
Mean 
2.374667 1252.782 3077.333 1.176667 
S.D. 0.000577 3.378835 21.00794 0.025166 
 
 
Linearity and Calibration Graph 
 
Figure 12. Chromatogram of 5 rpm 
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Assay of tablet Formulation 
Table 7. Result of Analysis for Olanzapine in tablet Formulation 
Std Conc. µg/ml Olanzapine 
10 
Rep-1 
10.10 
Rep-2 10.05 
Rep-3 10.08 
% found  *  
Rep-1 
101 
Rep-2 99.504 
Rep-3 100.298 
Mean 10.076 
SD 0.747 
% RSD 0.742 
*Each reading is mean reading of three batch of formulation 
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Validation of Developed Method 
Linearity 
Table 8. Response Ration Data for Linearity of Olanzapine 
Replicates 
Concentration 
(µg/ml) 
Mean AUC Response Ratio 
Rep-1 
5 
611.774 
122.3548 
Rep-2 10 1251.23 125.123 
Rep-3 15 1875.978 125.0652 
Rep-4 20 2483.22 124.161 
Rep-5 25 2982.129 119.2852 
Mean                                                                                123.197 
S.D.                                                                                   2.456 
R.S.D.                                                                                1.994 
 
 
 
Figure 13. Response Ratio Curve of Olanzapine 
 
Series2
Series1
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Result of Accuarcy 
Table 9. Recovery Studies of Formulation 
Level of Recovery 
(%) 
80 100 120 
Olanzapine Olanzapine Olanzapine 
Amount present 
(mg) 
10 
10 
10 
10 
10 
10 
10 
10 
10 
Amount of Std. 
added 
(mg) 
8 
8 
8 
10 
10 
10 
12 
12 
12 
Amount 
recovered 
(mg) 
7.98 
8.01 
8.00 
10.05 
10.00 
9.98 
11.95 
12.01 
11.95 
 
% Recovery 
 
99.75 
100.12 
100.00 
100.50 
100.00 
99.80 
99.58 
100.08 
99.58 
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Table 10. Statistical Validation of Recovery Studies 
Level of Recovery 
(%) 
Drug % Recovery Standard 
Deviation* 
% RSD 
80 Olanzapine 99.958 0.191 0.191 
100 Olanzapine 100.100 0.361 0.360 
120 Olanzapine 99.750 0.289 0.289 
*Denotes average of three determinations 
 
Result of precision 
(A) Repeatability 
Table 11. Results of analysis Data of Tablet Formulation 
 
(B) Intermediate Precision- (Inter-day and Intra-day Precision) 
Table 12. Intra-day and Inter-day Precision 
Drug Label claim 
 
Amount found* 
 
Label claim 
(%) 
S.D. % RSD 
Olanzapine 10  mg       9.95 99.50 0.254 0.125 
Intra-day Precision Inter-day Precision 
 % Label Claim  % Label Claim 
 Olanzapine  Olanzapine 
After 1hr 99.20 First day 97.50 
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Result of Robustness 
Table 13. Result of Robustness of Formulation 
Compound % RSD in Normal Changed Condition n= 6 
Temperature - 5 oC + 5 oC 
Olanzapine 0.54 0.69 0.52 
Flow rate (-10%) (+10%) 
Olanzapine 0.41 0.48 0.89 
Mobile phase ratio - 2 % + 2 % 
Olanzapine 0.31 0.77 0.15 
 
 
After 2hr 99.10 Second day 97.00 
After 3hr 99.00 Third day 96.80 
After 4hr 98.85   
After 5hr 98.70 
After 6hr 98.30 
Mean 98.97 Mean 97.1 
SD 
0.198746 
SD 
0.360555 
% RSD 
0.200814 
% RSD 
0.371324 
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Forced Degradation Studies 
Table 14. Forced degradation studies of Olanzapine 
Stress conditions Drug recovered (%) Drug decomposed 
(%) 
Standard drug                     99.90 0 
Acidic hydrolysis 83.26 16.64 
Alkaline hydrolysis 89.65 10.25 
Oxidative 
degradation 
91.23 
8.67 
Thermal degradation 98.89 1.01 
 
CONCLUSION 
The developed stability indicating HPLC method for quantitative estimation of olanzapine in 
bulk and pharmaceutical dosage forms is fast, simple, accurate, and more precise. Validation 
of this method was accomplished, getting results meeting all requirements. Thus, the 
developed HPLC method can be used for routine quality control test. 
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